BB Biotech AG : T3 en territoire négatif, la holding continue sa stratégie de réallocation
>Une perte nette de 157 MCHF au T3 - BB Biotech communique ce matin ses chiffres du T3 2024. Le rendement du titre ressort en territoire négatif à -9.2% en CHF et -6.7% en € et demeure négatif sur les 9 premiers mois de l’année à -11% (dividende inclus). La performance de son portefeuille au T3 ressort à -6.6% en CHF, -4.4% en € et -0.6% en $ sous-performant le Nasdaq Biotech Index (+5% en $ sur la période) mais ressort quasi-flat sur les 9 premiers mois de l’année à ...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.